EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation

Giuseppe Ciconte iD, Raffaele Salerno iD, Alessandro Fuga, Alessia Vuturo, Antonio Boccellino iD, Gabriele Negro iD, Roberto Rondine iD, Marco Ballarotto, Cristiano Ciaccio, Antonio Izzo, Davide Antonio Morciano iD, Arianna Garbelli iD und 5 weitere

Europace · 03.02.2026 · 28 (2)

DOI: 10.1093/europace/euag018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Europace, online erschienen am 10.02.2026. Verfasst von Giuseppe Ciconte und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Obesity, Glucagon-Like Peptides. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Italian Ministry of Health, IRCCS Policlinico San Donato.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Obesity adversely affects atrial fibrillation (AF) outcomes and is associated with higher recurrence after catheter ablation. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) promote weight loss and improve metabolic inflammation, but their role as adjuncts to ablation has not been completely defined. This study investigated the impact of semaglutide on post-ablation rhythm outcomes in obese patients with AF. Methods and results This single-centre, propensity-matched study included obese patients [body mass index (BMI) ≥ 30 kg/m²] undergoing first-time catheter ablation for paroxysmal AF (2019–2024). Patients who initiated semaglutide within 3 months before or 1 month after ablation were compared with matched controls who did not receive GLP-1RA therapy. All patients underwent continuous rhythm monitoring using implantable cardiac monitors. The primary endpoint was any atrial tachyarrhythmia recurrence beyond a 2-month blanking period. The final cohort included 181 semaglutide-treated patients and 181 controls with matched clinical and procedural characteristics. At 18-month follow-up, freedom from recurrence was 80.2% vs. 65.2%; semaglutide was associated with a significantly lower risk of recurrence (hazard ratio 0.52; 95% confidence interval 0.34–0.78; P = 0.002). Weight and BMI decreased significantly in the semaglutide group (−11.8 ± 3.8 kg; −4.0 ± 1.4 kg/m²) compared with controls (−1.9 ± 1.2 kg; −0.3 ± 0.8 kg/m²; both P < 0.001). A substantial proportion of treated patients achieved ≥10% weight reduction.

Conclusion

Glucagon-like peptide-1 receptor agonist therapy using semaglutide is associated with a reduced risk of AF recurrence in obese patients undergoing AF catheter ablation, indicating its potential as an adjunctive treatment. Further studies are needed to confirm these findings and elucidate the effects of GLP-1RA on AF recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationObesityGlucagon-Like PeptidesSemaglutideHumansFemaleMaleTreatment OutcomeMiddle AgedRecurrenceGlucagon-Like Peptide-1 Receptor AgonistsCombined Modality TherapyAgedRisk Factors

Stichwörter der Autor:innen

Atrial fibrillationCatheter ablationGLP-1 receptor agonistImplantable cardiac monitorsObesitySemaglutide

Substanzen

SemaglutideGlucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Vita-Salute San Raffaele University, Milan, Italy.
  • Arrhythmia and Electrophysiology Centre, IRCCS Policlinico San Donato, Piazza E. Malan 1, San Donato Milanese, Milan 20097, Italy.
  • Institute for Molecular and Translational Cardiology (IMTC), IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.

ORCID-Profile: Giuseppe Ciconte, Raffaele Salerno, Antonio Boccellino, Gabriele Negro, Roberto Rondine, Davide Antonio Morciano, Arianna Garbelli, Luigi Giannelli, Vincenzo Maiolo, Luigi Anastasia, Carlo Pappone

Förderung

  • Italian Ministry of Health
  • IRCCS Policlinico San Donato

Zitieren

APA

Ciconte, G., Salerno, R., Fuga, A., Vuturo, A., Boccellino, A., Negro, G., Rondine, R., Ballarotto, M., Ciaccio, C., Izzo, A., Morciano, D. A., Garbelli, A., Giannelli, L., Maiolo, V., Calovic, Z., Anastasia, L., & Pappone, C. (2026). Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation. Europace, 28(2). https://doi.org/10.1093/europace/euag018

Vancouver

Ciconte G, Salerno R, Fuga A, Vuturo A, Boccellino A, Negro G, et al. Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation. Europace. 2026;28(2). doi:10.1093/europace/euag018

BibTeX
@article{Ciconte2026,
  author = {Ciconte, Giuseppe and Salerno, Raffaele and Fuga, Alessandro and Vuturo, Alessia and Boccellino, Antonio and Negro, Gabriele and Rondine, Roberto and Ballarotto, Marco and Ciaccio, Cristiano and Izzo, Antonio and Morciano, Davide Antonio and Garbelli, Arianna and Giannelli, Luigi and Maiolo, Vincenzo and Calovic, Zarko and Anastasia, Luigi and Pappone, Carlo},
  title = {Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation},
  journal = {Europace},
  year = {2026},
  volume = {28},
  number = {2},
  doi = {10.1093/europace/euag018}
}
Kostenlos starten →